ASP Isotopes develops proprietary isotope enrichment technologies—including its Aerodynamic Separation Process and Quantum Enrichment methods—to produce high-value stable and specialist isotopes. Its targets include nuclear medicine (such as molybdenum and ytterbium isotopes), semiconductors, and advanced nuclear fuels including HALEU-related materials. Production and R&D are centered on facilities in South Africa, and the group also has a stake in nuclear medicine services through PET Labs in southern Africa.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.2 | — | -75.1 | — |
| Q3 2025 | 4.9 | — | -12.9 | — |
| Q4 2025 | 16.7 | — | -78.7 | — |
| Q1 2026 | 4.2 | — | -6.9 | — |
| Q2 2026 | 5.1 | 327.6% | -33.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Sizzle Acquisition Corp. II (SZZL), Aldel Financial II Inc. (ALDF), Crescent Capital BDC, Inc. (CCAP), Pioneer Acquisition I Corp (PACH), Cadiz Inc. (CDZI), Orchestra BioMed Holdings, Inc. (OBIO)